Each week, Clinical Trials Arena journalists analyse data on patent filings and grants that illustrate innovation trends in our sector. These patent signals show where the leading companies are focusing their research and development investment, and why. We uncover key innovation areas in the sector and the themes that drive them.
This new thematic patents coverage is powered by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.
This week, we examine GlobalData patent analytics of assignees and therapy trends for patent filings in the pharmaceutics landscape over Q2 2023. In this period, the Chinese Academy of Sciences led the number of patents filed for, with F. Hoffman-La Roche and LG Corp right behind.
The analysis demonstrated that the Beijing, China-based company had 947 total publications, 616 applications and 324 grants, showing prospective revenue streams for them. Grants here refer to approved documents by the patent office after document examination and criteria satisfaction.
Most patents filed were related to severe acute respiratory syndrome (SARS), inflammation, Diabetes, and Alzheimer’s diseases, which show recent trends in clinical trials for these therapy areas.
